



Customer No. 22,852  
Attorney Docket No.: 02356.0091

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Ara HOVANESSIAN et al.

Group Art Unit: 1646

**Application No.: 10/820,816**

**Examiner: Not Yet Assigned**

Filed: April 9, 2004

**For: NOVEL SYNTHETIC PEPTIDE VACCINES  
FOR HIV: THE CBD EPI TOPE AS AN EFFECTIVE  
IMMUNOGEN TO ELICIT BROADLY  
NEUTRALIZING ANTIBODIES AGAINST HIV**

**MAIL STOP MISSING PARTS**  
**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

Sir:

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURE**

Customer No. 22,852  
Attorney Docket No.: **02356.0091**

Authorization is hereby given to charge any additional fees to our deposit  
account no. 06-0916.

Please associate this new Oath or Declaration, substitute sequence listing  
in written form and in CRF and statement with the application as filed on April 9,  
2004 and assigned serial number 10/820,816.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: January 27, 2005

By: 

Ernest F. Chapman  
Reg. No. 25,961

Enclosures  
EFC/FPD/sci



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/820,816	04/09/2004	Ara Hovanessian	02356.0091

Finnegan, Henderson, Farabow,  
 Garrett & Dunner, L.L.P.  
 1300 I Street, N.W.  
 Washington, DC 20005-3315



CONFIRMATION NO. 9491

## FORMALITIES LETTER



\*OC000000013928197\*

Date Mailed: 09/29/2004

# NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

*Filing Date Granted*

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

## Items Required To Avoid Processing Delays:

The item(s) indicated below are also required and should be submitted with any reply to this notice to avoid further processing delays.

- A new oath or declaration, identifying this application number is required. The oath or declaration does not comply with 37 CFR 1.63 in that it:
- does not identify the citizenship of each inventor.

Replies should be mailed to: Mail Stop Missing Parts

Commissioner for Patents  
P.O. Box 1450  
Alexandria VA 22313-1450

---

*A copy of this notice **MUST** be returned with the reply.*

Meaza W  
Customer Service Center  
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



## DECLARATION

In re Patent Application of Hovanessian Ara et al having U.S. Patent Application Serial No. 10/820,816 filed on April 09, 2004, for NOVEL SYNTHETIC PEPTIDE VACCINES FOR HIV: THE CBD EPITOPE AS AN EFFECTIVE IMMUNOGEN TO ELICIT BROADLY NEUTRALIZING ANTIBODIES AGAINST HIV.

I prepared the electronic version and the paper copy of the Sequence Listing in connection with the above-captioned U.S. Patent application. The Sequence Listing information recorded in the computer readable form is identical to the written paper Sequence Listing.

November 23, 2004  
Paris, November 23, 2004

Julia Ziurys  
Julia ZIURYS